Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes.

Onset of Type 2 diabetes occurs when the pancreatic beta-cell fails to adapt to the increased insulin demand caused by insulin resistance. Morphological and therapeutic intervention studies have uncovered an inflammatory process in islets of patients with Type 2 diabetes characterized by the presence of cytokines, immune cells, beta-cell apoptosis, amyloid deposits, and fibrosis. This insulitis is due to a pathological activation of the innate immune system by metabolic stress and governed by IL-1 signaling. We propose that this insulitis contributes to the decrease in beta-cell mass and the impaired insulin secretion observed in patients with Type 2 diabetes.

[1]  H. Ellingsgaard,et al.  Pancreatic islet inflammation in type 2 diabetes: From α and β cell compensation to dysfunction , 2009, Archives of physiology and biochemistry.

[2]  G. Lacraz,et al.  Islet Endothelial Activation and Oxidative Stress Gene Expression Is Reduced by IL-1Ra Treatment in the Type 2 Diabetic GK Rat , 2009, PloS one.

[3]  J. Holst,et al.  Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. , 2009, American journal of physiology. Endocrinology and metabolism.

[4]  G. Lacraz,et al.  IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat , 2009, Proceedings of the National Academy of Sciences.

[5]  R. DeFronzo,et al.  Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons , 2009, Proceedings of the National Academy of Sciences.

[6]  A. Vaag,et al.  Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2009, Diabetes Care.

[7]  N. Morgan,et al.  Islet-associated macrophages in type 2 diabetes , 2009, Diabetologia.

[8]  A. Goldfine,et al.  Getting away from glucose: fanning the flames of obesity-induced inflammation , 2009, Nature Medicine.

[9]  S. Mohr,et al.  Differential regulation of high glucose-induced glyceraldehyde-3-phosphate dehydrogenase nuclear accumulation in Müller cells by IL-1beta and IL-6. , 2009, Investigative ophthalmology & visual science.

[10]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[11]  O. Wiklund,et al.  Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. , 2009, Atherosclerosis.

[12]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[13]  L. Senelick.  It (review) , 2008 .

[14]  L. O’Neill,et al.  The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.

[15]  G. Hotamisligil,et al.  Nutrient sensing and inflammation in metabolic diseases , 2008, Nature Reviews Immunology.

[16]  P. Halban,et al.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  R. Ye,et al.  Cutting Edge: TLR2 Is a Functional Receptor for Acute-Phase Serum Amyloid A1 , 2008, The Journal of Immunology.

[18]  Qin Wang,et al.  Requirements of calcium fluxes and ERK kinase activation for glucose- and interleukin-1β-induced β-cell apoptosis , 2008, Molecular and Cellular Biochemistry.

[19]  M. Donath,et al.  The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[20]  N. Kaiser,et al.  Impaired Glucose-Stimulated Insulin Secretion Is Coupled With Exocrine Pancreatic Lesions in the Cohen Diabetic Rat , 2008, Diabetes.

[21]  C. Glass,et al.  A Subpopulation of Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via Toll-like Receptors 2 and 4 and JNK-dependent Pathways* , 2007, Journal of Biological Chemistry.

[22]  H. Ellingsgaard,et al.  Increased Number of Islet-Associated Macrophages in Type 2 Diabetes , 2007, Diabetes.

[23]  S. Malozowski,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[24]  S. Devaraj,et al.  High glucose induces IL-1beta expression in human monocytes: mechanistic insights. , 2007, American journal of physiology. Endocrinology and metabolism.

[25]  J. Ferrières,et al.  Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.

[26]  S Kumar,et al.  Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[27]  M. Kurrer,et al.  The Fas pathway is involved in pancreatic β cell secretory function , 2007, Proceedings of the National Academy of Sciences.

[28]  I. Deary,et al.  The effects of acute hypoglycaemia on memory acquisition and recall and prospective memory in type 1 diabetes , 2006, Diabetologia.

[29]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[30]  C. Burant,et al.  Islet Microvasculature in Islet Hyperplasia and Failure in a Model of Type 2 Diabetes , 2006, Diabetes.

[31]  H. Ellingsgaard,et al.  Low Concentration of Interleukin-1β Induces FLICE-Inhibitory Protein–Mediated β-Cell Proliferation in Human Pancreatic Islets , 2006, Diabetes.

[32]  J. Senn.  Toll-like Receptor-2 Is Essential for the Development of Palmitate-induced Insulin Resistance in Myotubes* , 2006, Journal of Biological Chemistry.

[33]  James D. Johnson,et al.  Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1) , 2006, Proceedings of the National Academy of Sciences.

[34]  J. B. Kim,et al.  Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. , 2006, Biochemical and biophysical research communications.

[35]  M. Prentki,et al.  Islet beta cell failure in type 2 diabetes. , 2006, The Journal of clinical investigation.

[36]  H. Ellingsgaard,et al.  Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. , 2006, Diabetes.

[37]  R. Holle,et al.  Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). , 2005, Diabetes.

[38]  T. Mandrup-Poulsen,et al.  Interleukin-6 and diabetes: the good, the bad, or the indifferent? , 2005, Diabetes.

[39]  H. Ellingsgaard,et al.  Mechanisms of β-Cell Death in Type 2 Diabetes , 2005 .

[40]  P. Halban,et al.  Activation of NF-κB by Extracellular Matrix Is Involved in Spreading and Glucose-stimulated Insulin Secretion of Pancreatic Beta Cells* , 2005, Journal of Biological Chemistry.

[41]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[42]  Christopher J. Rhodes,et al.  Type 2 Diabetes-a Matter of ß-Cell Life and Death? , 2005, Science.

[43]  H. Edlund,et al.  Nuclear Factor-κB Activity in β-Cells Is Required for Glucose-Stimulated Insulin Secretion , 2005 .

[44]  H. Ellingsgaard,et al.  Mechanisms of beta-cell death in type 2 diabetes. , 2005, Diabetes.

[45]  C. Rhodes.  Type 2 diabetes-a matter of beta-cell life and death? , 2005, Science.

[46]  P. Halban,et al.  Activation of NF-kappaB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells. , 2005, The Journal of biological chemistry.

[47]  S. Bonner-Weir,et al.  Five stages of evolving beta-cell dysfunction during progression to diabetes. , 2004, Diabetes.

[48]  N. Stefan,et al.  Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. , 2004, Diabetes.

[49]  Per Westermark,et al.  Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[50]  P. Kern,et al.  Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. , 2004, American journal of physiology. Endocrinology and metabolism.

[51]  B. Wolf,et al.  Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. , 2004, Diabetes.

[52]  R. Robertson,et al.  β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes , 2004 .

[53]  T. Mandrup-Poulsen,et al.  The role of interleukin-1 in the pathogenesis of IDDM , 1996, Diabetologia.

[54]  R. Robertson,et al.  Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. , 2004, Diabetes.

[55]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[56]  R. Gomis,et al.  Evidence of expression of endotoxin receptors CD14, toll‐like receptors TLR4 and TLR2 and associated molecule MD‐2 and of sensitivity to endotoxin (LPS) in islet beta cells , 2003, Clinical and experimental immunology.

[57]  Kathrin Maedler,et al.  Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes , 2003, Journal of Molecular Medicine.

[58]  Jae-Hyoung Cho,et al.  Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea , 2003 .

[59]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[60]  In Kyu Lee,et al.  Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. , 2003, The Journal of clinical endocrinology and metabolism.

[61]  D. Ron,et al.  Endoplasmic reticulum stress and the development of diabetes: a review. , 2002, Diabetes.

[62]  M. Febbraio,et al.  Muscle‐derived interleukin‐6: mechanisms for activation and possible biological roles , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  F. Ris,et al.  FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[65]  M. Donath,et al.  Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. , 2001, Diabetes.

[66]  S. Rhee,et al.  Saturated Fatty Acids, but Not Unsaturated Fatty Acids, Induce the Expression of Cyclooxygenase-2 Mediated through Toll-like Receptor 4* , 2001, The Journal of Biological Chemistry.

[67]  S. Bonner-Weir.  Islet growth and development in the adult. , 2000, Journal of molecular endocrinology.

[68]  E. Cerasi,et al.  Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. , 1999, Diabetes.

[69]  B. Kahn.  Type 2 Diabetes: When Insulin Secretion Fails to Compensate for Insulin Resistance , 1998, Cell.

[70]  M. Mcdaniel,et al.  Evidence for the presence of type I IL-1 receptors on β-cells of islets of Langerhans , 1997 .

[71]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[72]  C. Wollheim,et al.  A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. , 1989, Journal of autoimmunity.

[73]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[74]  E. Cerasi,et al.  Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? , 1967, Acta endocrinologica.